PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2781470

[Hemosorption in systemic vasculitis].

N P Shilkina·Iu A Ganin·V I Alekseev·A G Pukhov
View original source ↗Export metadata ↓

Abstract

The present work summarises the experience gained with the use of extracorporeal hemoperfusion in 45 patients suffering from rheumatic diseases. During hemoperfusion, there was a decrease in the initially activated LDH, CPK, AST, ALT and AP. The reduction of the content of phospholipids and cholesterol in plasma and red blood cells is assessed as an adverse effect of hemoperfusion, since the content of phospholipids and cholesterol was under normal before hemoperfusion. The changes indicated point to the necessity of administering antioxidants and exogenous phospholipids.

Explore related subjects

CholesterolHemoperfusionHumansPhospholipidsVasculitisEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N P Shilkina, Iu A Ganin, V I Alekseev, A G Pukhov. 1989. [Hemosorption in systemic vasculitis].. https://pubmed.ncbi.nlm.nih.gov/2781470/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

MCA/MR syndrome with hypocholesterolemia related to familial dominant hypobetalipoproteinemia.

Recent reports have emphasized the role of cholesterol in vertebrate embryonic development. The RSH or so-called Smith-Lemli-Opitz syndrome (SLOS) was the first multiple congenital anomalies/mental retardation syndrome related to a cholesterol synthesis disturbance. Familial hypobetalipoproteinemia is a well-known dominantly inherited entity in which affected individuals usually are free of symptoms. We report on the unusual association of a malformation syndrome with mental retardation resembling SLOS and profound hypocholesterolemia related to familial hypobetalipoproteinemia. We discuss the possible causal relationship between the two conditions and the current understanding of the role of cholesterol in normal embryogenesis.

Cholesterol↗
PubMed2003

Thiazolidinediones and blood lipids in type 2 diabetes.

We evaluated study population characteristics and treatment effects on blood lipids between studies in which either rosiglitazone (RSG) or pioglitazone (PIO) was investigated in patients with type 2 diabetes. We performed a summary analysis of all published double-blind, placebo-controlled studies with RSG (4 and 8 mg/d) and PIO (15, 30, and 45 mg/d). Data were analyzed by the random-effects model. Nineteen trials met our inclusion criteria, yielding 5304 patients, 3236 in studies with RSG and 2068 in studies with PIO. Subjects treated with PIO were more obese and showed more pronounced hyperglycemia and dyslipidemia (increased triglycerides and decreased HDL cholesterol) at baseline than did subjects treated with RSG. By weighted linear-regression analysis, studies with PIO showed greater beneficial effects on triglycerides, total cholesterol, and LDL cholesterol, after adjustment for the respective lipid levels at baseline. RSG 8 mg/d showed greater increases in total cholesterol and LDL cholesterol than did RSG 4 mg/d. PIO 30 mg/d showed greater reductions in triglycerides than did PIO 15 mg/d. Studies conducted with PIO showed more beneficial effects on blood lipids, but also different study population characteristics in comparison with studies conducted with RSG. Differences in both pharmacologic properties between agents and study population characteristics are likely to have influenced the results.

Cholesterol↗